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Abstract
Background: The daily use of Trimethoprim-Sulfamethoxazole (TMP-SMX) prophylaxis reduces morbidity and mortality
among patients infected with Human Immunodeficiency Virus (HIV) but its impact on increasing antimicrobial resistance rates
has been of public concern globally. This study investigated the effect of daily TMP-SMX prophylaxis on faecal carriage rates
of resistant isolates of Escherichia coli in HIV-infected adult patients in Lagos.
Methods: A total of 550 HIV-infected patients with CD4-cell count of less than 350 cell/mm3 and were eligible for TMP-SMX
prophylaxis attending Lagos University Teaching Hospital, Lagos, Nigeria, were recruited. Stool/rectal swab samples were
aseptically collected from the patients and processed using standard methods for culture and sensitivity.
Results: There was a baseline Trimethoprim-Sulfamethoxazole resistance rate of 54% which increased to 77.9% in first 3
months, rising to 96.1% by 6 months and all isolates were resistant by the 9th month. There was also evidence of cross-
resistance to other antibiotics with significant association with TMP-SMX resistance (p<0.0001). The Escherichia coli isolates
showed a progressive increase in resistance to the tested antibiotics over the 12-month period. The resistance was in the
following order: Ampicillin (74% to 82.6% in the first 3 months; 98.3% by the 6th month and 99.4% by the 9th month; all
isolates were resistant by the 12th month). Augmentin (32.5% to 47.7% in first 3 months; 76.1% by the 6th month; 86.3% by
the 9th month; all isolates were resistant by 12 months). Ceftriaxone (2.0% to 10.8% in first 3 months; 20.6% by the 6th month;
24.2% by the 9th month; 54.3% by the 12 months).
Conclusion: The carriage rate of faecal E. coli resistant to TMP-SMX is common before TMP-SMX prophylaxis. Initiation of
TMP-SMX leads to further increase in resistance to TMP-SMX and cross-resistance to other antimicrobials.
Key-words: Trimethoprim- Sulfamethoxazole, HIV, Escherichia coli, Drug resistance, Prophylaxis.
Introduction
Patients infected with Human immunodeficiency virus (HIV) are at increased risk of opportunistic infections mainly due
to Mycobacterium tuberculosis, Staphylococcus aureus, Streptococcus pneumoniae, and Enterobactereceae. In sub-Saharan
Africa, these infections account for over 90% of morbidity and mortality found in these patients (WHO, 2006). However, the
conference convened by the Joint United Nations Program on HIV/AIDS (UNAIDS) and the World Health Organization in April
2000 recommended that Trimethoprim-Sulfamethoxazole (septrin) be used for prophylaxis in adults and children living with
HIV/AIDS in Africa as part of a minimum package of care for the prevention of opportunistic infections especially Pneumocystis
carrinii pneumonia (PCP) which is the most common presenting manifestation in Africa (UNAID/WHO, 2000).
This recommendation was based on the evidence from trials on Trimethoprim-Sulfamethoxazole prophylaxis
conducted in Africa, including Cote d’Ivoire, South Africa, Malawi, Zambia, and Uganda which showed significant reductions
in mortality of between 25% and 46% morbidity. This effect was also significant even in areas with high bacterial acquired
resistance (Grimwade et al., 2005; Werarak et al., 2006). This resulted in decreased frequency of clinic visits and
hospitalizations. Other studies carried out in Uganda and Zambia showed a beneficial effect of Trimethoprim-Sulfamethoxazole
prophylaxis on CD4 cell count and HIV viral load (Chintu et al., 2004; Mermin et al., 2004). In addition, it is inexpensive,
readily available and relatively safe (Castebon et al., 2001; Grimwade et al., 2001). Septrin and the related compound
sulfadoxine-pyrimethamine play central roles in the management of common clinical syndromes in Africa. These drugs are
frequently used to treat dysentery, lower respiratory tract infection, and fever in which Shigella spp., non-Typhi serotypes of
Salmonella enterica, Streptococcus pneumoniae, and Plasmodium spp., respectively, play major roles. It follows that increases
in resistance to septrin among these pathogens could reduce the effectiveness of empiric treatment strategies, leading to more
illness and death. Therefore concern was raised that the widespread use of SXT may substantially increase the prevalence of
antimicrobial resistance in common community-acquired pathogens.
The continuous exposure of bacteria to antibiotics leads to antibiotic resistance from selective pressure. Trimethoprim-
Sulfamethoxazole prophylaxis creates such a selective pressure (Cotton et al., 2008) on Escherichia coli which is a normal
commensal in the gastrointestinal tract (GIT) of humans. The large microbial population in the GIT (over 109/ml of
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faeces) allow for the easy transmission of antimicrobial resistant elements between various organisms and E. coli has been shown
to be a source of resistant gene to Salmonella, Shigella, Yersina, and Vibro species as well as potentially pathogenic Escherichia
coli (Chiller et al., 2003; Chikwendu et al., 2008). We therefore decided to evaluate the impact of Trimethoprim-
Sulfamethoxazole prophylaxis on antimicrobial resistance using Escherichia coli as an indicator.
Materials and Methods
Study Area and Population
The study was carried out in the Adult HIV Clinics of the Lagos University Teaching Hospital (LUTH) and the
National Institute for Medical Research (NIMR), Yaba both in Nigeria.
Study Design
The study was an incidence and a cross-sectional study.
Cross-sectional study
This was carried out over a 3 month period between February and April 2009 at the Adult HIV Clinics in LUTH Idi-
araba and NIMR Yaba, Lagos. A total of 550 (82.2%) participants out of the 669 patients that were diagnosed with HIV in that
period were recruited. Using the clinic register, every second patient that consented was recruited.
Incidence study
The 200 (20%) newly registered patients who had not commenced TMP-SMX prophylaxis out of the 2012 patients
attending the clinic that year were randomly recruited and followed up for a period of one year on outpatient basis. Also 120
participants who were not on TMP-SMX prophylaxis were recruited and followed up for one year as control. These were siblings
or spouses of the HIV-infected patients who regularly accompanied them to the clinic. They were HIV-negative and not on TMP-
SMX.
Ethical Consideration
The study was reviewed and approved by the ethical committee of the Lagos University Teaching Hospital according to
Helsinki Declaration. All patients were required to sign an informed consent and those that gave their consent were recruited.
Samples, data and results of patients were treated with utmost confidentiality and used for the purpose of this study only.
Sample collection
Stool samples were collected in sterile universal bottles. Three rectal swabs were collected from patients who could
not produce faeces. No patient was sampled more than once in the cross-sectional study while a repeat stool sample were
collected from all the new patients that were followed up as a cohort at their 3th, 6th, 9th and 12th month hospital visit. A two week
widow of opportunity before and after the expected date of collection was accepted. Stool and rectal swabs were immediately
taken to the laboratory of the Department of Medical Microbiology and Parasitology of the College of Medicine, University of
Lagos, Nigeria, and processed within one hour of collection.
Isolation and Identification of Escherichia coli
Faecal samples were inoculated directly onto MacConkey agar (OXOID) and incubated for 24 hours at 370C. From
each plate, three to five smooth, dry and flat colonies that were lactose fermenting were picked, and sub-cultured for purity. Pure
colonies were gram stained. If Gram negative, a part of one colony was picked and tested for motility. If motile, a part of the
same colony was sub-cultured and tested for indole. All indole positive, motile gram negative bacilli were further characterized
on the basis of their reactions to citrate, oxidase, urease, and growth characteristics on Kliager Iron Agar. All motile gram-
negative, oxidase and urea negative, indole positive, producing acid in both the butt and slant on KIA with greenish metallic-
sheen colonies on Eosin methylene blue (EMB) agar were presumed to be E. coli. These isolates were then stored on nutrient
agar (OXOID) slants for antibiotic susceptibility testing.
Antimicrobial Susceptibility Testing
The antimicrobial susceptibility tests were carried out using Kirby-Bauer disk diffusion method as recommended by
the Clinical and Laboratory Standards Institute (CLSI, 2009a). The antibiotics tested were: ceftriaxone (30∝g), ciprofloxacin
(5∝g), amoxicillin/clavulanate (20/10µg), gentamicin (10µg), ampicillin (10µg), imipenem (30µg) and trimethoprim-
sulfamethoxazole (1.25/23.75µg). Escherichia Coli ATCC 25922 strain was used as a control.
All antibiotic discs were allowed to equilibrate to room temperature before use. Isolates with zones of inhibition to
TMP-SMX above 16mm were considered sensitive while those less than 10mm were considered resistant. The Minimum
inhibitory concentrations (MIC) of these resistant isolates were carried out using E-test method to confirm resistance of these
drugs in accordance to the CLSI methodology (CLSI, 2009b).
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TMP-SMX resistant isolates were further screened for j3-lactamase production using a nitrocephin disc. All isolates that were
resistant to 3rd generation cephalosporin were tested for extended j3-lactamase (ESBL) production (CLSI, 2009b). ESBL was
determined according to the criteria of the Clinical and Laboratory Standards Institute (CLSI) by means of a double disk
diffusion method12.
Statistical analysis: The Epi-Info software 6.04 version (World Health Organization) was used for data analysis.
Results
Socio-Demographic Characteristics
A total of 550 were recruited into a cross sectional study and the effect of TMP-SMX prophylaxis on intestinal
isolates of E. coli evaluated at pre-TMP-SMX prophylaxis (0) and at 3rd, 6th, 9th, and 12th month prophylaxis. The mean age of
the participants was 35.6 ± 9.1, about half (52%) were married while the male to female ratio was 1:1.4. All participants came
from socio-economically deprived settings with 18.2 % being Unemployed, 11.1 % Artisans and 11.6% Traders. The
participant’s ability to read and write was low; 40.4 % attended primary school, 43.4 % secondary school and 8.6% had no
formal education. The median income level was ₦6,500.00 per month, with on average of 5 persons per household, translating 
into ₦217.00/person/day. Nine (1.6%) patients were hospitalized within the last three months, 28 (5.1%) took over the counter 
antimicrobial use in the preceding month, and 17 (3.1%) took herbal medications within the last three months.
Among the controls, the mean age was 34.9 ± 4. 57.5% were married while the male to female ratio was 1:1.6. Also all
participants came from socio-economically deprived settings with 14.2 % being Unemployed, 12.5 % Artisans, and 17.5% were
Traders. The participant’s ability to read and write was low; 34.0 % attended primary school, 51.0% secondary school and 7.0%
had no formal education. The median income level was ₦6,250.00 per month, with on average of 5 persons per household, 
translating into ₦208.00/person/day. Sixty-two (11.3%) took over the counter antimicrobial use in the preceding month, and 34 
(6.2%) took herbal medications within the last three months.
Cross Sectional Study
Carriage rate of TMP-SMX resistance of faecal Escherichia coli.
The carriage rate of TMP-SMX resistant isolates of E. coli (PLATE 1) varied between the different groups of
patients. One hundred and eight (54%) of the 200 isolates (0 month) were resistant. And of the each of 100 participants, 80% of
the isolates were resistant at 3 month visit, 97% at 6 month visit, 99% at 9 month visit, and 100% at 12 month visit (Figure 1).
There was an increasing trend in TMP-SMX resistance among each group of patients. However, there is statistically significant
difference between TMP-SMX resistance at 3 months and that of 0 month (p=0.001) and also between TMP-SMX resistance at
6 months and that of 3 months (p=0.001). There was no statistically difference between TMP-SMX resistance at 9 months and 6
months (p=0.07) as well as between 12 months and 9 months.
TMP-SMX resistance and antibiotic resistance profile.
Co-selection of antimicrobial resistance was assessed among all the isolates. With the commencement of TMP-SMX
prophylaxis, TMP-SMX resistance was found to be strongly associated with cross resistance to all other antimicrobial tested
except Imipenem (Figure 2) (p<0.000001).
Risk factors for Acquisition of TMP-SMX Resistance.
Multivariate logistics was done which showed that the use of Ampiclox and Sulfadoxine-pyrimethamine at the
preceding month predict TMP-SMX resistance (OR 8.05, CI 1.78-36.49, p< 0.007) and (OR 12.14, CI 1.53-96.07, p<0.018)
respectively. This was irrespective of the patients̕ educational or income level, occupation; length of hospital stay or intake of
herbal medicine and acquisition of either j3-lactamase or extended spectrum j3-lactamases (ESBL).
Figure 1: Carriage rate of resistant E. coli among the various groups of patients.
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Figure 2: Association of TMP-SMX resistance and antibiotic resistance profile.
Cohort study
Of the 200 patients recruited, loss to follow-up occurred in both the study participants and the control. Five (2.5%)
were lost at three month visit, 15(7.7%) at six month, 19 (10.5%) at nine month, and 10(6.6%) at twelve month visit. Of the 120
controls recruited, 1 (0.8%) were lost at three month visit, 8 (6.7%) at six month, and 11 (9.9%) at nine and none at twelve
month visit.
Carriage rate of resistant Escherichia coli isolates due to TMP-SMX prophylaxis.
The carriage rate of TMP-SMX resistance varied at each hospital visit between the participants and the control. Among
the participants, the carriage rate of TMP-SMX resistant isolates was 108 (54.0%) at 0 month, 152 (77.9%) at 3 months, 173
(96.1%) at 6 months and 161 (100.0%) at 9 months, and 151(100%) at 12 months while that of the control was 35(29.2%) at 0
month, 33 (27.7%) at 3 months, 34 (30.6%) at 6 months and 51 (51.0%) at 9 months, and 53(53.0%) at 12 month Figure 3.The
difference in the increasing trend in TMP-SMX resistance and selection of TMP-SMX resistance among the participants were
because these patients were on TMP-SMX prophylaxis. However, there is statistically significant difference between TMP-SMX
resistance among the participants when compared with the control at each hospital visit starting from the baseline (p=0.001), at 3
months (p=0.0001), at 6 months (p=0.0001), at 9 months (p=0.001), and at 12 months (p=0.0001).
Figure 3: Carriage rate of resistant Escherichia coli isolates due to TMP-SMX
prophylaxis. Effect of TMP-SMX prophylaxis on antibiotic resistance profile.
Co-selection of antimicrobial resistance due to TMP-SMX prophylaxis was also assessed among all the isolates of
both the study participants each hospital visit. The association of other antibiotic tested to septrin prophylaxis is shown in Figure
4. This was found to be statistically significant. This revealed that the longer the patient is on TMP-SMX, the higher chance of
developing resistance (p=0.0001).
Risk factors for Acquisition of Resistance.
Among the controls, there was a gradual increase in trend of TMP-SMX resistance (Figure 3). This increase was
attributed to the use of Ampiclox and Sulfadoxine-Pyrimethamine in the preceding month which was found to be strongly
associated with TMP-SMX resistance (OR 10.05, CI 1.92-36.49, p< 0.005) and (OR 11.04, CI 1.45-94.06, p<0.002)
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respectively. This was also irrespective of the patients̕ educational or income level, occupation; length of hospital stay or intake
of herbal medicine and acquisition of either j3-lactamase or extended spectrum j3-lactamases (ESBL) (p≤ 0.0001). 
Figure 4: Effect of TMP-SMX prophylaxis on antibiotic resistance
profile. Effect of TMP-SMX prophylaxis on Acquisition of resistance.
The association of acquisition of resistance to TMP-SMX resistance is shown in Figure 5. This was also found to be
statistically significant among the participants group than the control (p=0.001). This revealed that the longer the patient is on
TMP-SMX, the higher chance of developing resistance. The sensitivity test plates are shown before (PLATES 2, 3 and 4).
Figure 5: Effect of TMP-SMX prophylaxis and Acquisition of resistance.
Comparison of the carriage rate and the effect of TMP-SMX prophylaxis between cross sectional and cohort study. In
both studies, it was shown clearly that there was increasing trend in carriage rate of resistance E. coli isolates; Table1. There was
also an increasing trend in resistance between TMP-SMX prophylaxis and other antibiotics tested; Table 2. These validate the
hypothesis that initiation of TMP-SMX prophylaxis in HIV-infected individuals would lead to rapid and widespread resistance of
faecal E. coli to TMP-SMX.
Table 1: Carriage rate of resistant Escherichia coli isolates due to TMP-SMX prophylaxis.
0 200 108 54.0 200 108 54.0 120 35 29.2
3 100 89 89.0 195 152 77.9 119 33 27.7
6 100 97 97.0 180 173 96.1 111 34 30.6
9 100 99 99.0 161 161 100 100 51 51.0
12 100 99 99.0 151 151 100 100 53 53.0
N = total number
160
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Cross sectional study Cohort study
0 3 6 9 12 0 3 6 9 12
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Table 2: The Effect of septrin prophylaxis on antibiotic resistance profile.
Ampicillin 74.0 97.7 100.0 94.9 99.1 74.0 82.6 98.3 99.4 100.0
Augmentin 32.5 56.8 75.0 85.9 87.0 32.5 47.7 76.1 86.3 100.0
Ceftriaxone 2.0 2.3 4.0 4.0 24.0 2.0 10.8 20.6 24.2 54.3
Genticin 7.5 25.0 33.0 35.4 61.0 7.5 6.2 13.9 22.4 32.5
Ciprofloxacin 12.0 20.5 52.0 60.6 82.0 12.0 17.9 26.7 62.1 82.1
Imipenem 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Discussion
The effect of TMP-SMX prophylaxis on faecal carriage rates of resistant E. coli was studied to assess the role that TMP-
SMX in driving antimicrobial resistance. The carriage rate of TMP-SMX resistant E. coli even before the commencement of
TMP-SMX prophylaxis was 54%. This was similar with the recent observational cohort study done in Moshi, Tanzania on the
effect of TMP-SMX prophylaxis on antimicrobial resistance of faecal Escherichia coli in HIV- infected patients. Fifty-seven
faecal E. coli isolated from HIV-infected patients that were on TMP-SMX prophylaxis, 37(64.9%) were already resistant to TMP-
SMX before the commencement of TMP-SMX prophylaxis (Zachariah et al., 2002). Studies in East Africa and southern Africa
have also demonstrated such resistance in Enterobacteriaceae (Murray, 1987; van Oosterhout et al., 2005; WHO, 2007). Concern
about the impact of TMP-SMX resistance among key HIV bacterial copathogens on the efficacy of TMP-SMX prophylaxis has
been raised (Murray et al., 1983). Although large observational studies done in East Africa and southern Africa have shown that
TMP-SMX prophylaxis significantly reduces morbidity and mortality, even in settings where TMP-SMX prophylaxis is more
common (Buskin et al., 1999; Mwaungulu et al., 2004). No study that has investigated the magnitude of the effect of TMP-SMX
prophylaxis on resistance pattern of intestinal faecal flora.
In this study, most of those patients on TMP-SMX prophylaxis continued to carry TMP-SMX resistant E. coli at a
proportion higher than baseline. Furthermore, initiation of TMP-SMX prophylaxis rapidly leads to further loss of susceptibility
not only to TMP-SMX but to other important antimicrobial agents. This finding suggests that the impact of TMP-SMX
prophylaxis on antimicrobial resistance of bacterial flora occurs rapidly and that it is sustained as long as TMP-SMX
prophylaxis is continued. Although only the faecal indicator organism E. coli was studied there also is evidence from East
Africa that antimicrobial use is associated with the frequency of resistance among bacterial enteric pathogens. In Kenya,
resistance to antimicrobials among diarrheal non-Typhi Salmonella and Shigella spp. was inversely proportional to the
frequency with which the antimicrobials were prescribed, with TMP-SMX being the most common treatment prescription and
the least effective agent (Mermin et al., 2005a).
We demonstrated that the initiation of TMP-SMX prophylaxis not only selects for TMP-SMX resistant E. coli but also
seems to select for ampicillin, augmentin, ceftriaxone, genticin, and ciprofloxacin resistant. It is likely that a mechanism for the
coselection of resistance is by means of mobile genetic elements such as integrons in plasmids and transposons. Research on
enteroinvasive or enteroaggregative E. coli in Senegal showed that trimethoprim and other antimicrobial resistance was common
and that the mechanism was likely within the class 1 integron-containing plasmids that may be horizontally transferred from gut
commensal organisms (Hall et al., 1995; Gassama et al., 2004). In Tanzania, a study examining prevalence and mechanisms of
antimicrobial resistance among Shigella spp. from pediatric stool cultures found that resistance to ampicillin, chloramphenicol,
tetracycline, and TMP-SMX was common (Navia et al., 1999). Ampicillin resistance was most frequently related to an integron-
borne OXA-1-type b-lactamase, and resistance to TMP-SMX was attributable to the presence of an integron-borne dhfr Ia gene
(Gassama et al., 2004). Studies in Europe and Canada on uropathogenic E. coli that was resistant to trimethoprim,
sulfamethoxazole, or both found dfr or sul gene-containing integrons in 59% of isolates. Analysis of the regional distribution of
these integrons indicated that horizontal gene transfer was the main mechanism of resistance spread rather than clonal expansion
(Muray et al., 1983). These studies suggest that coselection of resistance by means of mobile genetic elements in faecal E. coli
attributable to TMP-SMX use is likely to occur and that these genetic elements can disseminate from faecal flora to bacterial
enteric pathogens.
This study also revealed that among the control group (those were not on TMP-SMX prophylaxis), gradual increase in
trend of TMP-SMX resistance was seen over time (Figure 4). This is in contrast to the study by Mermin et al. (2005b) in Uganda
which showed that antimicrobial resistance among diarrheal pathogens infecting family members did not increase. This increase
was attributed to the use of Ampiclox and Sulfadoxine-Pyrimethamine in the preceding month. This is due to abuse and misuse
of these antibiotics which are readily available at every patent medicine store of the country and are readily given out to these
patients by these unqualified medical personnel (Okeke et al., 1999). This study demonstrated that the carriage rate of faecal E.
coli resistant to TMP-SMX is common among HIV patients before the commencement of TMP-SMX prophylaxis. The carriage
rate went from 54% at baseline to 99% and 100% after one year in cross-sectional and cohort study respectively. This study also
revealed that septrin prophylaxis induces an accelerated selection of multi-drug resistant strains and co-selection to other
antibiotic classes as well (ampicllin, augmentin, ceftriaxone, ciprofloxacin, and genticin).
Finally, use of Ampiclox and Sulfadoxine-Pyrimethamine in the preceding month was found to predict Trimethoprim-
Sulfamethoxazole resistance among the case and control groups. This was irrespective of other risk factors like the patients̕
educational or income level, occupation; length of hospital stay or intake of herbal medicine and acquisition of either j3-
lactamase or extended spectrum j3-lactamses (ESBL).
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